Regeneron Pharmaceuticals, Inc. experienced a substantial stock drop exceeding 9% after its experimental melanoma treatment failed to meet key objectives in a late-stage study. The stock fell to $629.68, leading losses in both the S&P 500 and Nasdaq 100 indices, with premarket trading plunging an additional 11.21%. This decline intensifies bearish sentiment around the company, now down nearly 20% over recent weeks, as it faces mixed trial results and increasing competition.
“REGN · is priced at · 629.68 · -9.82%”
“REGN · has stock price · 629.68”
“REGN · Last · price · 629.68”
“REGN · Chg. % · change · -9.82%”
“REGN · Vol. · volume · 3.00M”
“Regeneron Pharmaceuticals · is down · more than -10% · to lead losers in the S&P 500 and Nasdaq 100”
“Regeneron Pharmaceuticals · declined · premarket trading · -11.21%”
“Regeneron Pharmaceuticals, Inc. · shares plunged · 9.8% · after its experimental melanoma treatment failed to achieve the main goal in a late-stage study”
“Regeneron Pharmaceuticals · closed · down · more than -9%”
“Regeneron Pharmaceuticals · is down · percentage · more than -10%”
“Regeneron Pharmaceuticals · has entered into · a strategic research collaboration · Parabilis Medicines”
“Regeneron Pharmaceuticals · shares · tank on announcement · failed to meet primary endpoint in Phase 3 trial”